Статья
Гипертонический криз у лиц пожилого возраста
Гипертонический криз – это внезапное повышение артериального давления (АД) до индивидуально высокого уровня, сопровождающееся клиническими симптомами, поражением органов-мишеней и требующее немедленного его снижения. C 2018 г. в Европе и c 2020 г. в России неосложненный гипертонический криз рекомендовано рассматривать в рамках злокачественной (неконтролируемой) артериальной гипертонии. Клиническая картина повышения АД у пожилых пациентов характеризуется неспецифическими симптомами, даже при развитии поражения органов-мишеней. Ведение этой группы пациентов требует от врача знания коморбидности пациента и списка принимаемых им препаратов на постоянной основе, чтобы минимизировать развитие побочных эффектов назначаемых препаратов и их нежелательное взаимодействие с плановой терапией.
1. World Health Organization. A global brief of hypertension. Silent killer, global public health crisis. World health day. 2013.
2. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive Urgencies and Emergencies: Prevalence and Clinical Presentation. Hypertension. 1996;27(1):144–7. DOI: 10.1161/01.HYP.27.1.144
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339
4. Patel KK, Young L, Howell EH, Hu B, Rutecki G, Thomas G et al. Characteristics and Outcomes of Patients Presenting With Hypertensive Urgency in the Office Setting. JAMA Internal Medicine. 2016;176(7):981–8. DOI: 10.1001/jamainternmed.2016.1509
5. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Артериальная гипертензия у взрослых. КР62. 2020. Доступно на: http://cr.rosminzdrav.ru/#!/schema/687
6. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e484–594. DOI: 10.1161/CIR.0000000000000596
7. Lip GY, Beevers M, Beevers G. The failure of malignant hypertension to decline: a survey of 24 years’ experience in a multiracial population in England. Journal of Hypertension. 1994;12(11):1297–305. PMID: 7868878
8. Marik PE, Varon J. Hypertensive Crises: challenges and management. Chest. 2007;131(6):1949–62. DOI: 10.1378/chest.06-2490
9. Chobanian AV. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 Report. JAMA. 2003;289(19):2560–72. DOI: 10.1001/jama.289.19.2560
10. Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M. Hypertension in the elderly. World Journal of Cardiology. 2012;4(5):135–47. DOI: 10.4330/wjc.v4.i5.135
11. Dharmashankar K, Widlansky ME. Vascular Endothelial Function and Hypertension: Insights and Directions. Current Hypertension Reports. 2010;12(6):448–55. DOI: 10.1007/s11906-010-0150-2
12. Varon J. Treatment of Acute Severe Hypertension: Current and Newer Agents. Drugs. 2008;68(3):283–97. DOI: 10.2165/00003495-200868030-00003
13. Singh M. Hypertensive crisis-pathophysiology, initial evaluation, and management. Journal of Indian College of Cardiology. 2011;1(1):36– 9.
14. Cowley AW, Lohmeier TE. Changes in renal vascular sensitivity and arterial pressure associated with sodium intake during long-term intrarenal norepinephrine infusion in dogs. Hypertension. 1979;1(6):549– 58. DOI: 10.1161/01.HYP.1.6.549
15. Pinna G, Pascale C, Fornengo P, Arras S, Piras C, Panzarasa P et al. Hospital Admissions for Hypertensive Crisis in the Emergency Departments: A Large Multicenter Italian Study. PLoS ONE. 2014;9(4):e93542. DOI: 10.1371/journal.pone.0093542
16. Elliott WJ. Clinical Features in the Management of Selected Hypertensive Emergencies. Progress in Cardiovascular Diseases. 2006;48(5):316–25. DOI: 10.1016/j.pcad.2006.02.004
17. Tulman DB, Stawicki SPA, Papadimos TJ, Murphy CV, Bergese SD. Advances in management of acute hypertension: a concise review. Discovery Medicine. 2012;13(72):375–83. PMID: 22642919
18. Muiesan ML, Salvetti M, Amadoro V, di Somma S, Perlini S, Semplicini A et al. An update on hypertensive emergencies and urgencies: Journal of Cardiovascular Medicine. 2015;16(5):372–82. DOI: 10.2459/JCM.0000000000000223
19. Li JZ, Eagle KA, Vaishnava P. Hypertensive and Acute Aortic Syndromes. Cardiology Clinics. 2013;31(4):493–501. DOI: 10.1016/j.ccl.2013.07.011
20. Gupta P, Gupta H, Khoynezhad A. Hypertensive Emergency in Aortic Dissection and Thoracic Aortic Aneurysm – A Review of Management. Pharmaceuticals. 2009;2(3):66–76. DOI: 10.3390/ph2030066
21. Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews. 2014;10:CD000039. DOI: 10.1002/14651858.CD000039.pub3
22. Butcher KS, Jeerakathil T, Hill M, Demchuk AM, Dowlatshahi D, Coutts SB et al. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke. 2013;44(3):620–6. DOI: 10.1161/STROKEAHA.111.000188
23. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C et al. Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. New England Journal of Medicine. 2013;368(25):2355– 65. DOI: 10.1056/NEJMoa1214609
24. Терещенко С.Н., Арутюнов Г.П., Галявич А.С., Гапонова Н.И., Гиляревский С.Р., Дупляков Д.В. и др. Неотложная помощь при внезапном выраженном индивидуально-значимом повышении артериального давления без клинически явного поражения органов-мишеней. Место каптоприла. Заключение Совета экспертов. Российский кардиологический журнал. 2020;25(2):103-10. DOI: 10.15829/1560-4071-2020-2-3748
25. Peixoto AJ. Acute Severe Hypertension. New England Journal of Medicine. 2019;381(19):1843–52. DOI: 10.1056/NEJMcp1901117
26. Недогода С.В., Кобалава Ж.Д., Конради А.О. Алгоритм ведения пациентов с артериальной гипертензией и гипертоническим кризом. Издание Российского кардиологического общества. 2019. Доступно на: https://scardio.ru/content/documents/algorythmy.pdf
27. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2015;63(11):2227–46. DOI: 10.1111/jgs.13702
28. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276(16):1328– 31. PMID: 8861992
29. Varon J, Marik PE. Clinical review: the management of hypertensive crises. Critical Care. 2003;7(5):374–84. DOI: 10.1186/cc2351
30. Weimann H-J, Rudolph M. Clinical Pharmacokinetics of Moxonidine. Journal of Cardiovascular Pharmacology. 1992;20(Suppl 4):S37–41. DOI: 10.1097/00005344-199220004-00008
31. Vallerand AH, Sanoski CA, Deglin JH. Davis’s drug guide for nurses. Fourteenth ed. -Philadelphia: F. A. Davis Company;2015. - 1489 p. ISBN 978-0-8036-4085-6
32. Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases: Clinical Pharmacokinetics. 1988;14(4):241–59. DOI: 10.2165/00003088-198814040-00002
33. Kazerani H, Hajimoradi B, Amini A, Naseri MH, Moharamzad Y. Clinical efficacy of sublingual captopril in the treatment of hypertensive urgency. Singapore Medical Journal. 2009;50(4):400–2. PMID: 19421685
34. Fumagalli C, Maurizi N, Marchionni N, Fornasari D. β-blockers: Their new life from hypertension to cancer and migraine. Pharmacological Research. 2020;151:104587. DOI: 10.1016/j.phrs.2019.104587
35. Grassi G. Metoprolol in the treatment of cardiovascular disease: a critical reappraisal. Current Medical Research and Opinion. 2018;34(9):1635–43. DOI: 10.1080/03007995.2018.1479245
36. The American Society of Health-System Pharmacists. Propranolol hydrochloride. 2015.
37. Tschollar W, Belz GG. Sublingual captopril in hypertensive crisis. The Lancet. 1985;326(8445):34–5. DOI: 10.1016/S0140-6736(85)90073-X
38. Pose Reino A, González-Juanatey JR, Fernández Velo JL, Amaro Cendón A, Bugallo Paz L, Gil de la Peña M. Sublingual enalapril in hypertensive crisis. A preliminary study. Anales De Medicina Interna. 1989;6(8):421–3. PMID: 2562344
39. Gokel Y, Satar S, Paydas S. A Comparison of the Effectiveness of Sublingual Losartan, Sublingual Captopril and Sublingual Nifedipine in Hypertensive Urgency. Turkish Journal of Medical Sciences. 1999;29:655–60.
40. Gemici K, Karakoç Y, Ersoy A, Baran I, Güllülü S, Cordan J. A comparison of safety and efficacy of sublingual captopril with sublingual nifedipine in hypertensive crisis. International Journal of Angiology. 2011;8(3):147–9. DOI: 10.1007/BF01616442
41. Divakaran S, Loscalzo J. The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics. Journal of the American College of Cardiology. 2017;70(19):2393–410. DOI: 10.1016/j.jacc.2017.09.1064
42. Marik PE, Rivera R. Hypertensive emergencies: an update. Current Opinion in Critical Care. 2011;17(6):569–80. DOI: 10.1097/MCC.0b013e32834cd31d
43. Ranadive SM, Eugene AR, Dillon G, Nicholson WT, Joyner MJ. Comparison of the vasodilatory effects of sodium nitroprusside vs. nitroglycerin. Journal of Applied Physiology. 2017;123(2):402–6. DOI: 10.1152/japplphysiol.00167.2017
44. Varon J, Marik PE. The Diagnosis and Management of Hypertensive Crises. Chest. 2000;118(1):214–27. DOI: 10.1378/chest.118.1.214
45. Sarafidis PA, Georgianos PI, Malindretos P, Liakopoulos V. Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opinion on Investigational Drugs. 2012;21(8):1089–106. DOI: 10.1517/13543784.2012.693477
46. Nightingale SL. From the Food and Drug Administration. JAMA. 1991;265(7):847. PMID: 1899454
47. Wood M, Hyman S, Wood AJ. A clinical study of sensitivity to sodium nitroprusside during controlled hypotensive anesthesia in young and elderly patients. Anesthesia and Analgesia. 1987;66(2):132–6. PMID: 3028217
48. Aronson S, Dyke CM, Stierer KA, Levy JH, Cheung AT, Lumb PD et al. The ECLIPSE Trials: Comparative Studies of Clevidipine to Nitroglycerin, Sodium Nitroprusside, and Nicardipine for Acute Hypertension Treatment in Cardiac Surgery Patients. Anesthesia & Analgesia. 2008;107(4):1110–21. DOI: 10.1213/ane.0b013e31818240db
49. Pongpanich P, Pitakpaiboonkul P, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. International Urology and Nephrology. 2018;50(12):2261–78. DOI: 10.1007/s11255-018-1991-x
50. Dowd FJ, Johnson BS, Mariotti AJ. Pharmacology and therapeutics for dentistry. Elsevier Health Sciences;2017. - 864 p. ISBN 978-0-323-39307-2
51. Michael RK, Ralph EC, Arden WF, Barbara MK. Pharmacokinetics of orally administered furosemide. Clinical Pharmacology & Therapeutics. 1974;15(2):178–86. DOI: 10.1002/cpt1974152178
52. Alijotas-Reig J, Bove-Farre I, de Cabo-Frances F, Angles-Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. The American Journal of Emergency Medicine. 2001;19(2):130– 3. DOI: 10.1053/ajem.2001.20008
53. Yang W, Zhou Y-J, Fu Y, Qin J, Qin S, Chen X-M et al. Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. Yonsei Medical Journal. 2017;58(1):105–13. DOI: 10.3349/ymj.2017.58.1.105